Grace Therapeutics Files Prospectus For Offering 4.762M Common Shares On Behalf Of Selling Shareholders
https://www.sec.gov/Archives/edgar/data/1444192/000114036126034189/ny20080485x1_s3.htm
Read original at benzingaStocks · News reference
Grace Therapeutics Receives FDA Meeting Minutes From Type A Meeting; FDA Confirms No Clinical Safety Or Efficacy Deficiencies
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical DataCompany Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 28, 2026, 11:06 AM
- Checked
- Jul 28, 2026, 11:06 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Grace Therapeutics Q1 EPS $(0.91) Misses $(0.18) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.18) by 405.56 percent. This is a 333.33 percent decrease over losses of $(0.21) per
Read original at benzinga8-K filing — Grace Therapeutics, Inc. (GRCE)
Filed: 2026-08-13 AccNo: 0001140361-26-032644 Size: 312 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarReported Earlier, Grace Therapeutics Prices Private Placement Of 4,761,904 Shares At $2.10 Per Share To Fund GTx-104 Manufacturing And Regulatory Work
Read original at benzinga